These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 23482732)

  • 1. Phentermine/topiramate for the treatment of obesity.
    Smith SM; Meyer M; Trinkley KE
    Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN
    Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
    Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
    Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
    Davidson MH; Tonstad S; Oparil S; Schwiers M; Day WW; Bowden CH
    Am J Cardiol; 2013 Apr; 111(8):1131-8. PubMed ID: 23375187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
    Allison DB; Gadde KM; Garvey WT; Peterson CA; Schwiers ML; Najarian T; Tam PY; Troupin B; Day WW
    Obesity (Silver Spring); 2012 Feb; 20(2):330-42. PubMed ID: 22051941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity.
    Hsia DS; Gosselin NH; Williams J; Farhat N; Marier JF; Shih W; Peterson C; Siegel R
    Diabetes Obes Metab; 2020 Apr; 22(4):480-491. PubMed ID: 31696603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
    Garvey WT; Ryan DH; Henry R; Bohannon NJ; Toplak H; Schwiers M; Troupin B; Day WW
    Diabetes Care; 2014 Apr; 37(4):912-21. PubMed ID: 24103901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.
    Prescrire Int; 2013 Mar; 22(136):61-4. PubMed ID: 23593686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
    Astrup A; Caterson I; Zelissen P; Guy-Grand B; Carruba M; Levy B; Sun X; Fitchet M
    Obes Res; 2004 Oct; 12(10):1658-69. PubMed ID: 15536230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and safety of the new anti-obesity medications.
    Hainer V; Aldhoon-Hainerová I
    Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA; Hollander P; Klein S; Kushner R; Levy B; Fitchet M; Perry BH
    Obes Res; 2003 Jun; 11(6):722-33. PubMed ID: 12805393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
    Guo F; Garvey WT
    Diabetes Care; 2017 Jul; 40(7):856-862. PubMed ID: 28455281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
    Woloshin S; Schwartz LM
    JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
    Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J
    Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.